Top Markets
Coin of the day
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

4598
Rank in Stocks #32530
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a... Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Share Price
$0.69158324
Market Cap
$9.84M
Change (1 day)
0.00%
Change (1 year)
-84.15%
Country
JP
Trade Delta-Fly Pharma, Inc. (4598)

Category

P/B ratio for Delta-Fly Pharma, Inc. (4598)
P/B ratio as of 2026 TTM: 0
According to Delta-Fly Pharma, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Delta-Fly Pharma, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE